Key Points
- · BioCryst
Pharmaceuticals completed the sale of its European ORLADEYO (berotralstat)
business to Neopharmed Gentili for $250 million upfront, plus potential future
milestones up to $14 million. - · The
transaction improves BioCryst’s operating margin and enhances cash flow
generation. - · This sale
aligns with BioCryst’s strategic focus on its core U.S. market opportunity. - · Neopharmed
Gentili retains the existing European commercial team for ORLADEYO. - · BioCryst
plans to use the proceeds to retire a $199 million Pharmakon term loan,
improving its balance sheet. - · Despite
divesting the European business, BioCryst maintains its 2025 revenue guidance
range of $580 million to $600 million. - · Neopharmed
Gentili views the acquisition as a significant step into the rare disease field
and international expansion. - · BioCryst will
continue to advance its U.S. ORLADEYO sales and pipeline of small-molecule and
protein therapeutics.
What is the nature of
BioCryst’s deal with Neopharmed Gentili?
As reported by multiple sources
including Charles Gayer, President and Chief Commercial Officer of BioCryst,
the company has successfully completed the sale of its European ORLADEYO
business to Neopharmed Gentili for an upfront payment of $250 million, subject
to customary purchase price adjustments, along with potential additional milestone
payments up to $14 million. This deal includes all European assets and rights
related to ORLADEYO (berotralstat).
Why did BioCryst sell its
European ORLADEYO business?
According to Jon Stonehouse,
President and CEO of BioCryst, the transaction is consistent with the company’s
strategy to streamline operations and focus on the U.S. market. The sale
unlocks significant value, helping BioCryst improve profitability by shedding a
lower-margin European segment and allowing the company to concentrate on its
core U.S. opportunities and pipeline development.
How will BioCryst use the
proceeds from the sale?
BioCryst plans to use the sale
proceeds, which notably exceed $250 million upfront, to retire its $199 million
Pharmakon term loan. This debt reduction enhances BioCryst’s financial
flexibility, improves its operating margin, and positions the company for future
strategic growth, including potential acquisitions or increased investment in
research and development.
What are the financial and
strategic impacts of this sale on BioCryst?
Charlie Gayer stated that the
transaction provides an immediate and significant improvement to BioCryst’s
operating margin and cash flow generation. Despite no longer including European
revenues, BioCryst remains on track to reach the upper half of its 2025 revenue
guidance range between $580 million and $600 million. The deal simplifies the
company’s business model, improves operational efficiency, and enhances
strategic optionality.
How will Neopharmed Gentili
manage ORLADEYO in Europe?
Neopharmed Gentili, a rapidly
growing Italian pharmaceutical company, will take over commercialization across
Europe, retaining the existing European commercial team to ensure a seamless
transition for ORLADEYO’s operations. Alessandro Del Bono, President and CEO of
Neopharmed Gentili, described the acquisition as a strategic move that projects
the company onto the international stage and into the rare disease market,
further consolidating its position as a leading European specialty pharma
company.
What is ORLADEYO, and why is it
important?
ORLADEYO (berotralstat) is an
oral medication used to prevent attacks of hereditary angioedema (HAE), a rare
genetic disorder characterised by recurrent swelling episodes. The drug is a
critical part of treatment for patients living with this condition, and
BioCryst continues to prioritise its development and sales in the U.S., where
it remains the core market for the company.
What other medicines and
developments is BioCryst pursuing?
Beyond ORLADEYO, BioCryst is
advancing a pipeline of small-molecule and protein therapies, including
candidates such as BCX10013, RAPIACTA, and PERAMIFLU. The company is focusing
its resources and investments mainly in the U.S. to drive future growth and
innovation in rare disease therapeutics.
